Do you want to read an article? Please log in or register.
Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL
Leukemia
Related content
Leukemia
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
J Clin Oncol
Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG
doi: 10.1200/JCO-25-02477
ASH 2025
BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL
Leukemia
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Blood
Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T
doi: 10.1182/blood.2024028205
ASH 2025
Leukemia
LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL
Genitourinary Cancer
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis
Int J Cancer
Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R
doi: 10.1002/ijc.70203
Leukemia
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial
Blood
Riecke A, Robrecht S, Yosifov DY, Schneider C, Giza A, Müller L, Vehling-Kaiser U, Eckart MJ, Freier W, Schöttker B, Gaska T, Reiser M, Fink AM, Fischer K, Eichhorst BF, Hallek MJ, Langerbeins P, Stilgenbauer S, Tausch E
doi: 10.1182/blood.2025032806
ASH 2025
Leukemia
AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL
Leukemia
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321
Br J Haematol
Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L
doi: 10.1111/bjh.70334
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022